Immunogenicity and safety of Advax™, a novel polysaccharide adjuvant based on delta inulin, when formulated with hepatitis B surface antigen: a randomized controlled Phase 1 study.

There is a need for additional safe and effective human vaccine adjuvants. Advax™ is a novel adjuvant produced from semi-crystalline particles of delta inulin. In animal studies Advax enhanced humoral and cellular immunity to hepatitis B surface antigen (HBsAg) without inducing local or systemic reactogenicity. This first-in-man Phase 1 clinical trial tested the safety and tolerability of three intramuscular doses of HBsAg formulated with Advax in a group of healthy adult subjects. Advax was well tolerated with injection site pain scores not significantly different to subjects receiving HBsAg alone and no adverse events were reported in subjects that received Advax. Seroprotection and HBsAb geometric mean titers (GMT) after three immunizations were higher in the Advax 5mg (seroprotection 5/6, 83.3%, GMT 40.7, 95% CI 11.9-139.1) and 10mg (seroprotection 4/5, 80%, GMT 51.6, 95% CI 10.0-266.2) groups versus HBsAg alone (seroprotection 1/5, 20%, GMT 4.1, 95% CI 1.3-12.8). Similarly the proportion of subjects with positive CD4 T-cell responses to HBsAg was higher in the Advax 5mg (4/6, 67%) and Advax 10mg (4/5, 80%) groups versus HBsAg alone (1/5, 20%). These results confirm the safety, tolerability and immunogenicity of Advax adjuvant observed in preclinical studies. Advax may represent a suitable replacement for alum adjuvants in prophylactic human vaccines subject to confirmation of current results in larger studies. Australia and New Zealand Clinical Trial Registry: ACTRN12607000598482.

[1]  G. D. Cioppa,et al.  Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age , 2011, Human vaccines.

[2]  D. Moher,et al.  CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials , 2010, BMJ : British Medical Journal.

[3]  J. Robson,et al.  The determination of the renal clearance of inulin in man. , 1949, Quarterly journal of experimental physiology.

[4]  M. Houghton,et al.  Priming of CD4+ and CD8+ T cell responses using a HCV core ISCOMATRIX™ vaccine: A phase I study in healthy volunteers , 2009, Human vaccines.

[5]  M. Lievens,et al.  Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients. , 2005, Kidney international.

[6]  P. Schur,et al.  Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. , 2014, Journal of autoimmunity.

[7]  N. Petrovsky,et al.  Advax-Adjuvanted Recombinant Protective Antigen Provides Protection against Inhalational Anthrax That Is Further Enhanced by Addition of Murabutide Adjuvant , 2014, Clinical and Vaccine Immunology.

[8]  F. Chisari,et al.  Enhanced immunogenicity of the pre-S region of hepatitis B surface antigen. , 1985, Science.

[9]  J. Mössner,et al.  HBV‐specific T‐cell responses in healthy seronegative sexual partners of patients with chronic HBV infection , 2009, Journal of viral hepatitis.

[10]  A. Bertoletti,et al.  Therapeutic vaccination and novel strategies to treat chronic HBV infection , 2009, Expert review of gastroenterology & hepatology.

[11]  Y. Barenholz,et al.  Comparison between hepatitis B surface antigen (HBsAg) particles derived from mammalian cells (CHO) and yeast cells (Hansenula polymorpha): composition, structure and immunogenicity. , 1997, Vaccine.

[12]  N. Petrovsky,et al.  A novel hepatitis B vaccine containing Advax™, a polysaccharide adjuvant derived from delta inulin, induces robust humoral and cellular immunity with minimal reactogenicity in preclinical testing. , 2013, Vaccine.

[13]  Y. Shoenfeld,et al.  Autoimmune/inflammatory syndrome induced by adjuvants (Shoenfeld’s syndrome): clinical and immunological spectrum , 2013, Expert review of clinical immunology.

[14]  F. André.  Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. , 1989, The American journal of medicine.

[15]  N. Petrovsky,et al.  Inulin isoforms differ by repeated additions of one crystal unit cell. , 2014, Carbohydrate polymers.

[16]  J. D. de Sanctis,et al.  An overview of adjuvant formulations and delivery systems , 2014, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[17]  A. Iasonos,et al.  Pilot Study of a Heptavalent Vaccine-Keyhole Limpet Hemocyanin Conjugate plus QS21 in Patients with Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer , 2007, Clinical Cancer Research.

[18]  N. Petrovsky,et al.  An Inactivated Cell Culture Japanese Encephalitis Vaccine (JE-ADVAX) Formulated with Delta Inulin Adjuvant Provides Robust Heterologous Protection against West Nile Encephalitis via Cross-Protective Memory B Cells and Neutralizing Antibody , 2013, Journal of Virology.

[19]  P. Laforêt,et al.  Macrophagic myofasciitis: an emerging entity , 1998, The Lancet.

[20]  C. Cooper,et al.  CPG 7909, an Immunostimulatory TLR9 Agonist Oligodeoxynucleotide, as Adjuvant to Engerix-B® HBV Vaccine in Healthy Adults: A Double-Blind Phase I/II Study , 2004, Journal of Clinical Immunology.

[21]  N. Petrovsky,et al.  Delta inulin: a novel, immunologically active, stable packing structure comprising β-D-[2 -> 1] poly(fructo-furanosyl) α-D-glucose polymers. , 2011, Glycobiology.

[22]  N. Petrovsky,et al.  Vaccine adjuvants: Current state and future trends , 2004, Immunology and cell biology.

[23]  G. Keating,et al.  Recombinant Hepatitis B Vaccine (Engerix-B®) , 2012, Drugs.

[24]  P. Messa,et al.  Hepatitis B virus vaccine in chronic kidney disease: improved immunogenicity by adjuvants? A meta-analysis of randomized trials. , 2012, Vaccine.

[25]  N. Petrovsky,et al.  Induction of mucosal and systemic antibody and T-cell responses following prime–boost immunization with novel adjuvanted human immunodeficiency virus-1-vaccine formulations , 2011, The Journal of general virology.

[26]  N. Petrovsky,et al.  Advax™, a polysaccharide adjuvant derived from delta inulin, provides improved influenza vaccine protection through broad-based enhancement of adaptive immune responses. , 2012, Vaccine.

[27]  N. Petrovsky,et al.  Analysis of the hydrolysis of inulin using real time 1H NMR spectroscopy. , 2012, Carbohydrate research.

[28]  G. Martínez-Bonilla,et al.  Adverse events following immunization with vaccines containing adjuvants , 2013, Immunologic Research.

[29]  A. Thomas,et al.  Effect of adjuvant on reactogenicity and long-term immunogenicity of the malaria Vaccine ICC-1132 in macaques. , 2005, Vaccine.

[30]  Y. Shoenfeld,et al.  Sjögren's syndrome: another facet of the autoimmune/inflammatory syndrome induced by adjuvants (ASIA). , 2014, Journal of autoimmunity.

[31]  W. Jilg,et al.  Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. , 2006, Vaccine.

[32]  Nikolai Petrovsky,et al.  Randomized clinical trial of immunogenicity and safety of a recombinant H1N1/2009 pandemic influenza vaccine containing Advax™ polysaccharide adjuvant. , 2012, Vaccine.

[33]  H. Panitch,et al.  Induction of recurrent experimental allergic encephalomyelitis with myelin basic protein , 1981, Annals of neurology.

[34]  Ke Xu,et al.  Immune response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults. , 2014, Vaccine.

[35]  N. Petrovsky,et al.  The polysaccharide inulin is characterized by an extensive series of periodic isoforms with varying biological actions. , 2013, Glycobiology.

[36]  H. W. Smith,et al.  THE EXCRETION OF INULIN, XYLOSE AND UREA BY NORMAL AND PHLORIZINIZED MAN. , 1935, The Journal of clinical investigation.

[37]  N. Petrovsky,et al.  An inactivated Vero cell-grown Japanese encephalitis vaccine formulated with Advax, a novel inulin-based adjuvant, induces protective neutralizing antibody against homologous and heterologous flaviviruses , 2010, The Journal of general virology.

[38]  M. Kundi,et al.  Antibody-response to three recombinant hepatitis B vaccines: comparative evaluation of multicenter travel-clinic based experience. , 2001, Vaccine.

[39]  P. Skinhøj,et al.  A 2-Dose Regimen of a Recombinant Hepatitis B Vaccine with the Immune Stimulant AS04 Compared with the Standard 3-Dose Regimen of Engerix-B in Healthy Young Adults , 2002, Scandinavian journal of infectious diseases.

[40]  O. Götze,et al.  THE C3-ACTIVATOR SYSTEM: AN ALTERNATE PATHWAY OF COMPLEMENT ACTIVATION , 1971, The Journal of experimental medicine.

[41]  G. Leroux-Roels,et al.  Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. , 2008, Vaccine.

[42]  A. B. Lyons,et al.  Determination of lymphocyte division by flow cytometry. , 1994, Journal of immunological methods.

[43]  Raw,et al.  Safety and immunogenicity of hepatitis B vaccine ButaNG in adults , 1999, Revista do Instituto de Medicina Tropical de Sao Paulo.

[44]  L. Marnell,et al.  C-reactive protein: ligands, receptors and role in inflammation. , 2005, Clinical immunology.

[45]  R. Deth,et al.  How aluminum adjuvants could promote and enhance non-target IgE synthesis in a genetically-vulnerable sub-population , 2013, Journal of immunotoxicology.

[46]  C. Shaw,et al.  Aluminum in the central nervous system (CNS): toxicity in humans and animals, vaccine adjuvants, and autoimmunity , 2013, Immunologic research.

[47]  C. Cooper,et al.  Hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine: a review of HEPLISAV™ safety and efficacy , 2011, Expert review of vaccines.

[48]  R. Janssen,et al.  Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age. , 2013, Vaccine.

[49]  R. C. Layton,et al.  Delta inulin polysaccharide adjuvant enhances the ability of split-virion H5N1 vaccine to protect against lethal challenge in ferrets. , 2011, Vaccine.

[50]  N. Petrovsky,et al.  JE-ADVAX Vaccine Protection against Japanese Encephalitis Virus Mediated by Memory B Cells in the Absence of CD8+ T Cells and Pre-Exposure Neutralizing Antibody , 2013, Journal of Virology.

[51]  E. Oviedo-Orta,et al.  Progress in understanding adjuvant immunotoxicity mechanisms. , 2011, Toxicology letters.